Recent News

• 06.30.2026 - Vamorolone Demonstrates On-Target Glucocorticoid Activity Without the Immunosuppression Characteristic of Traditional Corticosteroids at Clinical Doses
• 05.11.2026 - Catalyst Pharmaceuticals Reports First Quarter 2026 Financial Results
• 05.07.2026 - Catalyst Pharmaceuticals Cancels First Quarter 2026 Conference Call and Webcast
• 05.07.2026 - Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® (amifampridine) Patent Litigation with Hetero Labs Ltd.
• 04.28.2026 - Catalyst Pharmaceuticals to Report First Quarter 2026 Financial Results on May 11, 2026
• 03.06.2026 - Catalyst Pharmaceuticals to Showcase Real‑World Findings in Duchenne Muscular Dystrophy and Host Vamorolone-Focused Symposium at the 2026 MDA Clinical & Scientific Conference
• 02.25.2026 - Catalyst Pharmaceuticals Reports Record Fourth Quarter and Record Full Year 2025 Financial Results and Provides 2026 Financial Guidance
• 02.24.2026 - Catalyst Pharmaceuticals to Participate in the Barclays 28th Annual Global Healthcare Conference
• 02.11.2026 - Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2025 Financial Results on February 25, 2026
• 01.08.2026 - Catalyst Pharmaceuticals Receives Prestigious Ranking on Forbes 2026 List of America's Most Successful Small-Cap Companies

Recent Filings

• 07.08.2026 - 8-K Current report
• 06.30.2026 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
• 06.30.2026 - 8-K Current report
• 06.30.2026 - EX-99.1 EX-99.1
• 06.23.2026 - 8-K Current report
• 06.08.2026 - DEFM14A Definitive proxy statement relating to merger or acquisition
• 06.05.2026 - 4 Statement of changes in beneficial ownership of securities
• 05.28.2026 - PREM14A Preliminary proxy statements relating to merger or acquisition
• 05.12.2026 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
• 05.11.2026 - 8-K Current report